Joel G. Turner, Ph.D.
Affiliations: | 2008 | University of South Florida, Tampa, FL, United States |
Area:
Molecular Biology, Oncology, PharmacologyGoogle:
"Joel Turner"Parents
Sign in to add mentor| James R. Garey | grad student | 2008 | University of South Florida | |
| (Drug resistance to topoisomerase directed chemotherapy in human multiple myeloma.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Turner JG, Cui Y, Bauer AA, et al. (2020) Melphalan and exportin 1 inhibitors exert synergistic anti-tumor effects in preclinical models of human multiple myeloma. Cancer Research |
| Sweet K, Komrokji RS, Padron E, et al. (2019) Phase I clinical trial of selinexor in combination with daunorubicin and cytarabine in previously untreated poor-risk acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Turner JG, Dawson J, Bauer A, et al. (2019) Abstract 285: Ixazomib combined with the nuclear export inhibitors selinexor or eltanexor for the treatment of multiple myeloma Cancer Research |
| Turner JG. (2017) Abstract 4049: The synergistic effect of melphalan and XPO1 inhibition in preclinical models of multiple myeloma Cancer Research. 77: 4049-4049 |
| Turner JG, Kashyap T, Dawson JL, et al. (2016) XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget |
| Turner JG, Dawson JL, Grant S, et al. (2016) Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. Journal of Hematology & Oncology. 9: 73 |
| Baz RC, Shain KH, Alsina M, et al. (2016) Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM). Journal of Clinical Oncology. 34: 8013-8013 |
| Cui Y, Turner JG, Dawson JL, et al. (2016) The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma Blood. 128: 5662-5662 |
| Cornell RF, Rossi AC, Baz R, et al. (2016) A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma Blood. 128: 4509-4509 |
| Turner JG, Kashyap T, Dawson JL, et al. (2016) Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma Blood. 128: 3299-3299 |